View PDF Version - RePub - Erasmus Universiteit Rotterdam

More documents

Recommendations

Info

Chapter 4.2 192 ABSTRACT Tenofovir, an antihuman immunodefi ciency virus (HIV) drug, has activity against lamivudine-resistant hepatitis B virus (HBV) mutants. To describe the effi cacy of tenofovir in patients with lamivudine-resistant hepatitis B we applied two investigative approaches based on mathematical models of viral dynamics: the individual nonlinear fi tting and the mixed-effect group fi tting approaches. Eleven chronic HBV patients on lamivudine for a median of 176 weeks (range: 72–382) with YMDD mutation-related HBV-DNA breakthrough received ‘add-on’ tenofovir 300 mg once-daily, while maintaining their existing therapy. Sequential sera were taken at day 1 (t = 0 and t = 8 h), days 2, 4, 7, 10, 14, 21, 28 and every 4 weeks thereafter, and HBV-DNA levels were assessed using a validated quantitative polymerase chain reaction (PCR) assay. Median baseline log HBV-DNA was 8.62 (range: 6.48 9.76 log HBV-DNA). Tenofovir treatment resulted in a mean (±SD) log HBV-DNA decline of 1.37 ± 0.51 in the fi rst phase, 2.54 ± 0.91 after 4 weeks, and 4.95 ± 0.90 log HBV-DNA after 24 weeks. The median effectiveness of blocking viral replication in the individual fit model was 93% (range: 73–99) for η=0 and 93% (range: 59–99) for η=1. There was only a small difference between the effi cacy parameter ‘ε’ of the individual nonlinear fi tting and mixed-effect group fi tting on the biphasic exponential model. These data show that tenofovir has good effi cacy in blocking viral replication in HBV patients with lamivudine induced drug-resistant HBV mutants, but effectiveness varies greatly among individuals. Both models can be used to describe viral decay during tenofovir therapy.
INTRODUCTION Viral dynamics during tenofovir therapy 193 Treatment of hepatitis B virus (HBV) infection with standard interferon-α produces a durable response in one-fi fth to one-third of patients but has undesirable side-effects and must be administered subcutaneously three times per week. 1–3 Although lamivudine treatment also produces a modest response rate with few side-effects, prolonged treatment is often necessary to prevent relapse on cessation of therapy, and continuous treatment can lead to the development of lamivudine resistance. 4–5 Phenotypic lamivudine resistance, with the emergence of YMDD drug-resistant mutants in the polymerase gene of the HBV, leads to an increase in serum HBV-DNA levels. This suggests that there is a clinical need for new antiviral agents that adequately inhibit DNA-polymerase activity, both in wild type and in mutant virus populations. The search for drug-resistant mutants is usually initiated after an increase in serum HBV- DNA load has been observed. 6 Studies have shown that the lamivudine mutations are localized in two major domains of the reverse transcriptase (RT) region of the polymerase gene. 7–8 Analyses of the YMDD region of the C-domain of the polymerase gene have shown that, in the case of resistance, methionine (rtM204) is replaced either by valine (rtM204V), isoleucine (rtM204I) or serine (rtM204S). The valine (rtM204V) variant is, in most cases, accompanied by another mutation (leucine to methionine; rtL180M) in the B-domain. 9 A mixture of YMDD variants can exist in one individual. Tenofovir disoproxil fumarate, an acyclic nucleotide analogue RT inhibitor, appears to be effective against the YMDD drug-resistant mutant population. In vitro studies, tenofovir demonstrated a combination of low cytotoxicity and antiviral effi cacy. It was equally effective at inhibiting wild-type HBV-DNA replication and at inhibiting DNA replication in the YMDD variant, rtM180V. 10 Clinical studies investigating the effect of tenofovir on HBV replication have shown that it has signifi cant activity against lamivudineresistant mutants both in chronic HBV patients and in human immunodefi ciency virus (HIV)/HBV co-infected patients. 11–17 Mathematical modelling provides a tool for evaluating the effect of antiviral therapy. It can provide insight into the speed and variability in patterns of viral decay, which may be useful in the design of future treatment strategies. The decay curve of HBV during therapy with nucleoside analogues exhibits a biphasic decline during the fi rst 4 weeks of treatment. Analysis of these viral kinetics can be used to calculate both the effectiveness of therapy in inhibiting viral production as well as the clearance of cells infected with HBV. We have used two previously published models to describe viral decline during treatment in chronic hepatitis B patients and investigate the viral dynamics of HBV replication after the addition of tenofovir to lamivudine therapy. 18–19
Page 1:
Statistical Models of Treatment Eff
Page 4 and 5:
ISBN: 978-90-8559-069-9 © Bettina
Page 6 and 7:
PROMOTIECOMMISSIE Promotor: Prof.dr
Page 9 and 10:
CONTENTS Chapter 1. Introduction 11
Page 13:
Cha pter 1 Introduction
Page 16 and 17:
Chapter 1 14 Epidemiology Worldwide
Page 18 and 19:
Chapter 1 16 Prediction models with
Page 20 and 21:
Chapter 1 18 standard method fails
Page 22 and 23:
Chapter 1 20 The extended non-linea
Page 24 and 25:
Chapter 1 22 References 1. Blumberg
Page 27:
Cha pter 2 Prediction of response t
Page 30 and 31:
Chapter 2.1 28 ABSTRACT The aim of
Page 32 and 33:
Chapter 2.1 30 been hepatitis B sur
Page 34 and 35:
Chapter 2.1 32 HBV DNA decline The
Page 36 and 37:
Chapter 2.1 34 Figure 2 continued.
Page 38 and 39:
Chapter 2.1 36 Figure 4. Estimated
Page 40 and 41:
Chapter 2.1 38 DNA was observed in
Page 42:
Chapter 2.1 40 15. Kao JH. Role of
Page 46 and 47:
Chapter 2.2 44 ABSTRACT Background:
Page 48 and 49:
Chapter 2.2 46 low baseline HBV DNA
Page 50 and 51:
Chapter 2.2 48 patient subgroups wa
Page 52 and 53:
Chapter 2.2 50 p=0.002). Previous I
Page 54 and 55:
Chapter 2.2 52 Application of the m
Page 56 and 57:
Chapter 2.2 54 PEG-IFN, the proport
Page 58 and 59:
Chapter 2.2 56 References 1. Lavanc
Page 60 and 61:
Chapter 2.2 58 26. Bonino F, Lau GK
Page 63 and 64:
Chap ter 2.3 Prediction of the resp
Page 65 and 66:
INTRODUCTION Dynamic prediction of
Page 67 and 68:
Statistical analysis Dynamic predic
Page 69 and 70:
Dynamic prediction of response to P
Page 71 and 72:
Page 73 and 74:
Page 75 and 76:
Page 77 and 78:
References Dynamic prediction of re
Page 81 and 82:
Cha pter 2.4 Dynamic prediction of
Page 83 and 84:
INTRODUCTION Dynamic prediction of
Page 85 and 86:
For the indirect approach we rewrit
Page 87 and 88:
logit pi,j = logit Pr(Ri =1|visit =
Page 89 and 90:
Dynamic prediction of response usin
Page 91 and 92:
Page 93 and 94:
Page 95 and 96:
Page 97 and 98:
Page 99 and 100:
Page 101 and 102:
Table 1. Results of different stopp
Page 103 and 104:
Page 105:
Page 108 and 109:
Chapter 2.5 106 ABSTRACT Peginterfe
Page 110 and 111:
Chapter 2.5 108 and placebo daily.
Page 112 and 113:
Chapter 2.5 110 for patients with a
Page 114 and 115:
Chapter 2.5 112 Mean HBV DNA declin
Page 116 and 117:
Chapter 2.5 114 peginterferon and n
Page 118 and 119:
Chapter 2.5 116 hepatocellular carc
Page 120 and 121:
Chapter 2.5 118 13. Werle-Lapostoll
Page 122:
Chapter 2.5 120 Greece - G Germanid
Page 127 and 128:
Chap ter 3.1 Long-term clinical out
Page 129 and 130:
INTRODUCTION Glycyrrhizin for IFN-n
Page 131 and 132:
Statistics Glycyrrhizin for IFN-non
Page 133 and 134:
Glycyrrhizin for IFN-non responders
Page 135 and 136:
Table 2. Time dependent Cox regress
Page 137 and 138:
Page 139 and 140:
Page 143 and 144: Cha pter 3.2 Discriminant analysis
Page 145 and 146: Introduction Discriminant analysis
Page 147 and 148: Discriminant analysis using a MLMM
Page 149 and 150: Estimation Discriminant analysis us
Page 153 and 154: where wi,k(y i, θ) = (k =1,...,K).
Page 171 and 172: Appendix Discriminant analysis usin
Page 175: Cha pter 4 Statistical models of ea
Page 178 and 179: Chapter 4.1 176 ABSTRACT Nucleoside
Page 180 and 181: Chapter 4.1 178 at day 1 at t =0 an
Page 182 and 183: Chapter 4.1 180 Table 1. Baseline c
Page 184 and 185: Chapter 4.1 182 Figure 1.
Page 186 and 187: Chapter 4.1 184 Figure 1. Viral dec
Page 188 and 189: Chapter 4.1 186 suppression in seru
Page 190 and 191: Chapter 4.1 188 13. Seifer M, Hamat
Page 193: Cha pter 4.2 Viral dynamics during
Page 197 and 198: Viral dynamics during tenofovir the
Page 201 and 202: log HBV DNA (copies/mL) 10.0 9.0 8.
Page 211 and 212: Chap ter 4.3 Modelling of early vir
Page 213 and 214: INTRODUCTION HBV viral kinetics dur
Page 215 and 216: HBV viral kinetics during PEG-IFN 2
Page 229: HBV viral kinetics during PEG-IFN 2
Page 233 and 234: SUMMARY AND CONCLUSION Summary and
Page 235 and 236: Summary and conclusion 233 The mode
Page 237 and 238: Summary and conclusion 235 The infe
Page 239: Summary and conclusion 237 Early st
Page 243 and 244: SAMENVATTING EN CONCLUSIE Samenvatt
Page 245 and 246:
Samenvatting en conclusie 243 Er we
Page 247 and 248:
Samenvatting en conclusie 245 Data
Page 249 and 250:
Samenvatting en conclusie 247 Behan
Page 253:
Dan kwoord
Page 256 and 257:
Dankwoord 254 Lieve Marion en Margr
Page 259 and 260:
BIBLI OGRAPHY Bibliography 257 1. K
Page 261 and 262:
Bibliography 259 Interferon-ribavir
Page 263 and 264:
Bibliography 261 Long term clinical
Page 265 and 266:
Bibliography 263 Flares in chronic
Page 267 and 268:
Bibliography 265 Genetic characteri
Page 269:
Bibliography 267 106. Reijnders JG,
show all

View PDF Version - RePub - Erasmus Universiteit Rotterdam

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?